Logo Medical Science Monitor

Call: +1.631.470.9640
Mon - Fri 10:00 am - 02:00 pm EST

Contact Us

Logo Medical Science Monitor Logo Medical Science Monitor Logo Medical Science Monitor

20 September 2021: Editorial  

Editorial: Autoantibodies to Components of the Immune System, Including Type 1 Interferons, and the Risk of Severe COVID-19

Dinah V. Parums1CDEF*

DOI: 10.12659/MSM.934766

Med Sci Monit 2021; 27:e934766

0 Comments

Abstract

ABSTRACT: During the past two years, clinical studies have attempted to identify risk factors to predict clinical outcomes following infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In July 2021, a study using a high-throughput technique detected autoantibodies to chemokines, cytokines, and complement components in patients with symptomatic coronavirus disease 2019 (COVID-19). In August 2021, a study identified pre-existing autoantibodies to type 1 interferons (IFNs) in 10% of patients with severe COVID-19 but not asymptomatic individuals. Autoantibodies may be the long-awaited markers of clinical risk for severe COVID-19 in patients with SARS-CoV-2 infection. This Editorial aims to present some recent findings of autoantibodies to components of the immune system, including type 1 IFNs, and the risk of severe COVID-19.

Keywords: Editorial, Autoantibodies, Interferons, Risk, severe acute respiratory syndrome coronavirus 2, COVID-19, COVID-19, Humans, Interferon Type I, SARS-CoV-2

During the past two years, observational clinical studies and population studies have attempted to identify risk factors to predict clinical outcomes following infection from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [1–4]. However, the risk factors for severe coronavirus disease 2019 (COVID-19) and the clinical outcomes are likely to vary between individuals [3–5]. These associations or general risk factors are not absolute, as severe disease and mortality from COVID-19 have been reported in young patients and previously healthy individuals [3,4].

In July 2021, the US National COVID Cohort Collaborative (N3C) Consortium reported the findings from a retrospective cohort study on the predictive factors associated with the development of severe COVID-19 [5]. The N3C study cohort included 174,568 adults with confirmed SARS-CoV-2 infection diagnosed between January 1, 2020, and December 7, 2020, the largest COVID-19 cohort currently evaluated [5]. In the study cohort, 18.6% of patients were hospitalized, and 20.2% required invasive ventilation [5]. Patient mortality, or discharge to hospice care, was reported in 11.6% of hospitalized patients with COVID-19 [5].

Therefore, there is still a need to understand why age and certain underlying health conditions increase the severity of COVID-19 and patient mortality [1]. Identifying risk factors or profiles for both susceptibility and severity of COVID-19 is of global importance for allocating healthcare resources during the COVID-19 pandemic [5,6].

In a publication in the journal Nature, in July 2021, Wang and colleagues reported using a high-throughput technique to detect autoantibodies to screen a cohort of 194 individuals with confirmed SARS-CoV-2 [7]. In this study, 172 patients had COVID-19, and 22 healthcare staff were asymptomatic or had mild symptoms [7]. The high-throughput screening method screened for autoantibodies to 2,770 secreted and extracellular proteins [7]. Patients with symptomatic COVID-19 had a significant increase in autoantibody reactivity compared with non-infected individuals [7]. The screening method detected autoantibodies to chemokines, cytokines, and complement components, which are all immune modulators [7].

In August 2021, an international team of immunologists identified pre-existing autoantibodies to type 1 interferons (IFNs) in 10% of patients with severe COVID-19, but not in individuals with asymptomatic infection [8]. Immunologists at the Rockefeller University, New York City, led this international research team [8]. The study included 3,595 patients from 38 countries with confirmed severe COVID-19 admitted to intensive care units (ICUs) [8]. Of these critically ill patients, 13.6% had autoantibodies, and of the patients who died while in the ICU, 18% had autoantibodies [8]. In critically ill patients under 40 years of age, autoantibodies were present in 21% [8]. These neutralizing autoantibodies were to either IFN-α or IFN-ω, and 1.3% of patients with critical COVID-19 and 0.9% of patients who died had autoantibodies to IFN-β. [8]. The autoantibodies to IFNs were identified as a cause rather than a consequence of the development of severe COVID-19 [8]. In October 2020, this research group previously showed that autoantibodies were present in only 4 in 1,000 healthy people who had blood samples collected before the COVID-19 pandemic [9].

Several studies have reported an association between the reduced activity of IFNs and increased susceptibility to severe COVID-19 [10,11]. In October 2020, Zhang and colleagues reported that inborn errors of TLR3-dependent and IRF7-dependent type I IFN immunity were associated with severe and life-threatening COVID-19 pneumonia [10]. In August 2021, Asano and colleagues showed that individuals with genetic mutations that alter the activity of type 1 interferons were at increased risk of developing severe COVID-19 [11]. Type I IFNs have a key role in innate and adaptive immune cell responses during infection from organisms that include viruses [12]. Also, type I IFNs are involved in complex immuno-regulatory networks that usually, but not always, protect the host from infection, with minimal immunological damage to the host [12].

Conclusions

Ongoing studies have identified a possible role for autoantibodies in the development of clinically severe COVID-19. It is possible that autoantibodies to components of the immune system, which are either pre-existing or develop after infection, impair immune control of SARS-CoV-2. The role of autoantibodies to components of the immune system in the pathogenesis of COVID-19 may involve inhibition of immunoreceptor signaling or directly affect immune cells. There is the possibility that newly identified autoantibodies may be the long-awaited markers for clinical risk of severe COVID-19 in patients with SARS-CoV-2 infection.

References

1. Grasselli G, Greco M, Zanella ACOVID-19 Lombardy ICU Network, Risk factors associated with mortality among patients with COVID-19 in Intensive Care Units in Lombardy, Italy: JAMA Intern Med, 2020; 180(10); 1345-55

2. Costagliola G, Spada E, Consolini R, Age-related differences in the immune response could contribute to determine the spectrum of severity of COVID-19: Immun Inflamm Dis, 2021; 9(2); 331-39

3. Sandoval M, Nguyen DT, Vahidy FS, Graviss EA, Risk factors for severity of COVID-19 in hospital patients age 18–29 years: PLoS One, 2021; 16(7); e0255544

4. Wu Z, McGoogan JM, Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention: JAMA, 2020; 323; 1239-42

5. Bennett TD, Moffitt RA, Hajagos JGNational COVID Cohort Collaborative (N3C) Consortium, Clinical characterization and prediction of clinical severity of SARS-CoV-2 infection among US adults using data from the US National COVID Cohort Collaborative: JAMA Netw Open, 2021; 4(7); e2116901

6. Miller IF, Becker AD, Grenfell BT, Metcalf CJE, Disease and healthcare burden of COVID-19 in the United States: Nat Med, 2020; 26(8); 1212-17

7. Wang EY, Mao T, Klein J, Diverse functional autoantibodies in patients with COVID-19: Nature, 2021; 595(7866); 283-88

8. Bastard P, Gervais A, Le Voyer T, Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths: Sci Immunol, 2021; 6(62); eabl4340

9. Bastard P, Rosen LB, Zhang Q, Autoantibodies against type I IFNs in patients with life-threatening COVID-19: Science, 2020; 370(6515); eabd4585

10. Zhang Q, Bastard P, Liu Z, Inborn errors of type I IFN immunity in patients with life-threatening COVID-19: Science, 2020; 370(6515); eabd4570

11. Asano T, Boisson B, Onodi F, X-linked recessive TLR7 deficiency in ~10f men under 60 years old with life-threatening COVID-19: Sci Immunol, 2021; 6(62)

12. McNab F, Mayer-Barber K, Sher A, Type I interferons in infectious disease: Nat Rev Immunol, 2015; 15(2); 87-103

In Press

Clinical Research  

Anterior Plate-Supported Cannulated Screw Surgery for Ankle Arthrodesis: Clinical and Radiologic Results in...

Med Sci Monit In Press; DOI: 10.12659/MSM.944452  

Clinical Research  

Elevated Plasma Levels of Growth Arrest Specific 6 (Gas6) Protein in Severe Obesity: Implications for Adipo...

Med Sci Monit In Press; DOI: 10.12659/MSM.944462  

Database Analysis  

Systemic Immune-Inflammation Index (SII) as a Predictor of Short-Term Mortality Risk in Sepsis-Associated A...

Med Sci Monit In Press; DOI: 10.12659/MSM.943414  

Clinical Research  

Morphological Variations of the Nasopalatine Canal in the North Cyprus Population: A Cone Beam Computed Tom...

Med Sci Monit In Press; DOI: 10.12659/MSM.944868  

Most Viewed Current Articles

17 Jan 2024 : Review article   2,131,100

Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron Variant

DOI :10.12659/MSM.942799

Med Sci Monit 2024; 30:e942799

0:00

14 Dec 2022 : Clinical Research   1,555,090

Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase Levels

DOI :10.12659/MSM.937990

Med Sci Monit 2022; 28:e937990

0:00

16 May 2023 : Clinical Research   690,471

Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...

DOI :10.12659/MSM.940387

Med Sci Monit 2023; 29:e940387

0:00

01 Jan 2022 : Editorial   50,389

Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...

DOI :10.12659/MSM.935952

Med Sci Monit 2022; 28:e935952

0:00

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750